Thermo Fisher Scientific Inc. $TMO Shares Purchased by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 118,737 shares of the medical research company’s stock after purchasing an additional 1,456 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Thermo Fisher Scientific were worth $70,353,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in TMO. Brookstone Capital Management grew its stake in Thermo Fisher Scientific by 1.1% during the fourth quarter. Brookstone Capital Management now owns 8,548 shares of the medical research company’s stock worth $4,953,000 after buying an additional 96 shares during the period. apricus wealth LLC boosted its position in Thermo Fisher Scientific by 2.4% during the 4th quarter. apricus wealth LLC now owns 940 shares of the medical research company’s stock worth $545,000 after purchasing an additional 22 shares during the period. Northstar Advisory Group LLC acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at $3,250,000. Mn Services Vermogensbeheer B.V. raised its position in Thermo Fisher Scientific by 1.9% in the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 146,215 shares of the medical research company’s stock valued at $84,724,000 after purchasing an additional 2,715 shares during the period. Finally, Lantz Financial LLC purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth about $217,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Wells Fargo & Company set a $683.00 target price on Thermo Fisher Scientific in a report on Friday, January 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Friday, January 9th. DZ Bank initiated coverage on shares of Thermo Fisher Scientific in a research report on Friday, March 27th. They set a “buy” rating and a $610.00 target price on the stock. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Finally, The Goldman Sachs Group initiated coverage on shares of Thermo Fisher Scientific in a report on Tuesday, December 9th. They issued a “buy” rating and a $685.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $632.50.

Key Stories Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher launched the Thermo Scientific Glacios 3 Cryo-TEM, a next‑generation 200 kV cryo‑TEM targeted at structural biology labs — a product that can expand addressable markets for high‑margin instruments and support equipment sales and service revenue growth. Thermo Fisher Scientific Launches Thermo Scientific Glacios 3 Cryo-TEM
• Positive Sentiment: Positive investor commentary and momentum from recent quarterly results (strong EPS and revenue beat in late Jan.) have helped set expectations for a rally and a new 52‑week high, reinforcing investor confidence in execution and cash flow. Thermo Fisher Scientific (TMO) Sets Stage for Q4 Rally with Impressive Q3 Earnings and New 52-Week High
• Positive Sentiment: High‑profile endorsement: media coverage noting Jim Cramer called the company “unbelievable” has driven retail interest and contributed to the stock’s upward momentum, especially given TMO’s exposure to the booming biopharma/GLP‑1 supply chain. Thermo Fisher (TMO) Shares Up Since Jim Cramer Called the Firm “Unbelievable”
• Neutral Sentiment: Research coverage initiated at DZ Bank — adds institutional coverage and may improve liquidity and analyst visibility; impact depends on the tone of subsequent reports. Thermo Fisher Scientific (NYSE:TMO) Research Coverage Started at DZ Bank
• Negative Sentiment: Industry cost risk: multiple outlets cite analyst concerns that rising global helium prices (linked to geopolitical tensions) could increase operating costs for cryogenic instruments and consumables — a potential margin headwind for TMO’s instrument/service businesses. How is Thermo Fisher (TMO) Preparing to Deal With Rising Helium Prices
• Negative Sentiment: Small position trim: Beacon Investment Advisory sold 1,296 shares in Q4, shrinking its holding — a minor vote of caution but not material to TMO’s large shareholder base. Beacon Investment Advisory Services Inc. Sells 1,296 Shares of Thermo Fisher Scientific Inc. $TMO

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the completion of the transaction, the executive vice president directly owned 20,752 shares of the company’s stock, valued at $11,230,982.40. This trade represents a 1.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Up 2.5%

Shares of NYSE:TMO opened at $492.07 on Wednesday. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67. The firm has a market cap of $182.80 billion, a PE ratio of 27.74, a price-to-earnings-growth ratio of 2.77 and a beta of 0.96. The company has a fifty day simple moving average of $524.79 and a 200 day simple moving average of $548.30.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, topping the consensus estimate of $6.45 by $0.12. The company had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The firm’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period last year, the business earned $6.10 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Friday, March 13th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s payout ratio is 10.60%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.